GS-5734 and its parent nucleoside analog inhibit Filo-, Pneumo-, and Paramyxoviruses
Scientific Reports2017Vol. 7(1), pp. 43395–43395
Citations Over TimeTop 1% of 2017 papers
Michael K. Lo, Robert Jordan, Aaron Arvey, Jawahar Sudhamsu, Punya Shrivastava-Ranjan, Anne L. Hotard, Mike Flint, Laura K. McMullan, Dustin S. Siegel, Michael O. Clarke, Richard L. Mackman, Hon C. Hui, Michel Perron, Adrian S. Ray, Tomáš Cihlář, Stuart T. Nichol, Christina F. Spiropoulou
Abstract
GS-5734 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a non-human primate model of Ebola virus infection. It has been administered under compassionate use to two Ebola patients, both of whom survived, and is currently in Phase 2 clinical development for treatment of Ebola virus disease. Here we report the antiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, providing evidence to support new indications for this compound against human viruses of significant public health concern.
Related Papers
- → Tissue-Specific Proteomics Analysis of Anti-COVID-19 Nucleoside and Nucleotide Prodrug-Activating Enzymes Provides Insights into the Optimization of Prodrug Design and Pharmacotherapy Strategy(2021)15 cited
- → Prodrug Strategies in the Design of Nucleoside and Nucleotide Antiviral Therapeutics(2004)42 cited
- → Metabolism of Nucleosides and Nucleotides Prodrugs(2017)13 cited
- → Nucleoside transporter expression and adenosine uptake in the rat cochlea(2007)9 cited
- → NewCycloAMB-Nucleoside Phosphonate Prodrugs(2007)5 cited